{"id":"ergoloid-mesylates","rwe":[{"pmid":"41288280","year":"2025","title":"Prescription Trends of Potentially Inappropriate Medications and Anticholinergics in Ambulatory Older Adults With and Without Dementia: A Repeated Cross-sectional Analysis at a Tertiary Medical Center in Taiwan.","finding":"","journal":"Alzheimer disease and associated disorders","studyType":"Clinical Study"},{"pmid":"38325771","year":"2024","title":"DHEC mesylate attenuates pathologies and aberrant bisecting N-glycosylation in Alzheimer's disease models.","finding":"","journal":"Neuropharmacology","studyType":"Clinical Study"},{"pmid":"27037980","year":"2016","title":"Validated liquid chromatography-tandem mass spectrometry method for simultaneous determination of clopamide, reserpine and dihydroergotoxine: Application to pharmacokinetics in human plasma.","finding":"","journal":"Journal of pharmaceutical and biomedical analysis","studyType":"Clinical Study"},{"pmid":"25774185","year":"2012","title":"Yizhi Xingnao prescription improves the cognitive function of patients after a transient ischemic attack.","finding":"","journal":"Neural regeneration research","studyType":"Clinical Study"},{"pmid":"21553703","year":"2011","title":"Alternative drug therapies for dementia.","finding":"","journal":"Journal of psychosocial nursing and mental health services","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"C04AE01","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Dementia","category":"indication"},{"label":"Novartis","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-Antagonists","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Nootropic Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"transient","organSystem":""},{"effect":"Gastric disturbances","drugRate":"","severity":"transient","organSystem":""}],"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Novartis","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ERGOLOID MESYLATES","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:47:28.573650+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Ergoloid Mesylates","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:47:36.771807+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:47:35.384080+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ERGOLOID MESYLATES","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:47:36.006817+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Adrenergic receptor alpha antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:47:36.771477+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2311030/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:47:36.678587+00:00"}},"allNames":"hydergine","offLabel":[],"synonyms":["ergoloid mesylate","ergoloid mesylates","codergocrine mesilate","ergoloid mesilates","codergocrine","ergoloid","codergine mesylate","codergocrine methanesulfonate","ergoloid methanesulfonate","hydergine","dihydroergotoxine mesilate","dihydroergotoxine mesylate"],"timeline":[{"date":"1953-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from NOVARTIS to Novartis"},{"date":"1953-11-05","type":"positive","source":"DrugCentral","milestone":"FDA approval (Novartis)"},{"date":"1983-01-18","type":"positive","source":"FDA Orange Book","milestone":"Hydergine Lc approved — 1MG"}],"aiSummary":"Hydergine (Ergoloid Mesylates) is a small molecule medication originally developed by Novartis and currently owned by the same company. It was first approved by the FDA in 1953 for the treatment of dementia. Despite being off-patent, there are still 11 generic manufacturers available. Key safety considerations include its bioavailability of 25%. Hydergine's commercial status is generic, with no active Orange Book patents.","approvals":[{"date":"1953-11-05","orphan":false,"company":"NOVARTIS","regulator":"FDA"}],"brandName":"Hydergine","ecosystem":[{"indication":"Dementia","otherDrugs":[{"name":"dihydroergocornine","slug":"dihydroergocornine","company":""}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Ergoloid mesylates, the active ingredient in Hydergine, is a semisynthetic ergot alkaloid that acts as a vasodilator, increasing cerebral blood flow and oxygenation, which may help alleviate symptoms of dementia."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ergoloid","title":"Ergoloid","extract":"Ergoloid mesylates (USAN), co-dergocrine mesilate (BAN) or dihydroergotoxine mesylate, trade name Hydergine, is a mixture of the methanesulfonate salts of three dihydrogenated ergot alkaloids.","wiki_society_and_culture":"==Society and culture==\n===Brand names===\nBrand names include Hydergine, Hydergina, Gerimal, Niloric, Redizork, Alkergot, Cicanol, Redergin, and Hydrine."},"commercial":{"launchDate":"1953","_launchSource":"DrugCentral (FDA 1953-11-05, NOVARTIS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5035","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ERGOLOID%20MESYLATES","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ERGOLOID MESYLATES","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Ergoloid","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:01:04.553091","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:47:38.513926+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"ergoloid mesylates","indications":{"approved":[{"name":"Dementia","source":"DrugCentral","snomedId":52448006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Novartis","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT05030129","phase":"PHASE2","title":"ERG/5-HTP in Fragile X Syndrome (FXS)","status":"COMPLETED","sponsor":"Elizabeth Berry-Kravis","startDate":"2021-10-07","conditions":["Fragile X Syndrome"],"enrollment":15,"completionDate":"2023-01-19"},{"nctId":"NCT01475578","phase":"PHASE2","title":"Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)","status":"COMPLETED","sponsor":"Sinphar Pharmaceutical Co., Ltd","startDate":"2002-03","conditions":["Vascular Dementia"],"enrollment":240,"completionDate":"2002-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000181828","MMSL":"3561","NDDF":"000698","UNII":"X3S33EX3KW","VUID":"4030210","CHEBI":"CHEBI:34706","VANDF":"4017835","RXNORM":"151870","UMLSCUI":"C0014708","chemblId":"CHEMBL2311030","ChEMBL_ID":"CHEMBL2311030","KEGG_DRUG":"D02268","DRUGBANK_ID":"DB01049","PUBCHEM_CID":"592735","SNOMEDCT_US":"350622001","MESH_DESCRIPTOR_UI":"D004877"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1953-","companyName":"Novartis","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"25%"},"publicationCount":32,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"C04AE01","allCodes":["C04AE01","C04AE51"]},"biosimilarFilings":[],"originalDeveloper":"Novartis","recentPublications":[{"date":"2025 Oct-Dec 01","pmid":"41288280","title":"Prescription Trends of Potentially Inappropriate Medications and Anticholinergics in Ambulatory Older Adults With and Without Dementia: A Repeated Cross-sectional Analysis at a Tertiary Medical Center in Taiwan.","journal":"Alzheimer disease and associated disorders"},{"date":"2024 May 1","pmid":"38325771","title":"DHEC mesylate attenuates pathologies and aberrant bisecting N-glycosylation in Alzheimer's disease models.","journal":"Neuropharmacology"},{"date":"2016 Jun 5","pmid":"27037980","title":"Validated liquid chromatography-tandem mass spectrometry method for simultaneous determination of clopamide, reserpine and dihydroergotoxine: Application to pharmacokinetics in human plasma.","journal":"Journal of pharmaceutical and biomedical analysis"},{"date":"2012 Feb 25","pmid":"25774185","title":"Yizhi Xingnao prescription improves the cognitive function of patients after a transient ischemic attack.","journal":"Neural regeneration research"},{"date":"2011 May","pmid":"21553703","title":"Alternative drug therapies for dementia.","journal":"Journal of psychosocial nursing and mental health services"}],"companionDiagnostics":[],"genericManufacturers":11,"_genericFilersChecked":true,"genericManufacturerList":["3M","Bristol Myers Squibb","Ivax Pharms","Kv Pharm","Lederle","Mutual Pharm","Sandoz","Sun Pharm Industries","Superpharm","Vangard","Watson Labs"],"status":"approved","companyName":"Novartis","companyId":"novartis","modality":"Small Molecule","firstApprovalDate":"1953","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1953-11-05T00:00:00.000Z","mah":"NOVARTIS","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:47:38.513926+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}